nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA3—obesity	0.226	0.578	CbGaD
Nilotinib—MAPK8—obesity	0.165	0.422	CbGaD
Nilotinib—CA6—Topiramate—obesity	0.0335	0.11	CbGbCtD
Nilotinib—CA7—Topiramate—obesity	0.0292	0.0955	CbGbCtD
Nilotinib—CA9—Topiramate—obesity	0.025	0.0819	CbGbCtD
Nilotinib—CA12—Topiramate—obesity	0.025	0.0819	CbGbCtD
Nilotinib—CA1—Topiramate—obesity	0.0234	0.0767	CbGbCtD
Nilotinib—CA4—Topiramate—obesity	0.022	0.0721	CbGbCtD
Nilotinib—CA2—Topiramate—obesity	0.0202	0.0663	CbGbCtD
Nilotinib—CYP2B6—Benzphetamine—obesity	0.0166	0.0542	CbGbCtD
Nilotinib—CYP2B6—Bupropion—obesity	0.0141	0.0461	CbGbCtD
Nilotinib—CYP2C8—Bupropion—obesity	0.0107	0.0349	CbGbCtD
Nilotinib—CYP2C9—Phentermine—obesity	0.00875	0.0286	CbGbCtD
Nilotinib—CYP2D6—Phentermine—obesity	0.008	0.0262	CbGbCtD
Nilotinib—CYP2C8—Cimetidine—obesity	0.00783	0.0256	CbGbCtD
Nilotinib—CYP2C9—Bupropion—obesity	0.00744	0.0244	CbGbCtD
Nilotinib—CYP2D6—Bupropion—obesity	0.0068	0.0223	CbGbCtD
Nilotinib—CYP3A4—Sibutramine—obesity	0.00671	0.022	CbGbCtD
Nilotinib—CYP2D6—Methamphetamine—obesity	0.00639	0.0209	CbGbCtD
Nilotinib—CYP2C9—Cimetidine—obesity	0.00546	0.0179	CbGbCtD
Nilotinib—ABCB1—Cimetidine—obesity	0.0053	0.0173	CbGbCtD
Nilotinib—CYP3A4—Benzphetamine—obesity	0.00509	0.0167	CbGbCtD
Nilotinib—CYP2D6—Cimetidine—obesity	0.00499	0.0163	CbGbCtD
Nilotinib—CYP3A4—Bupropion—obesity	0.00433	0.0142	CbGbCtD
Nilotinib—CYP3A4—Orlistat—obesity	0.00353	0.0115	CbGbCtD
Nilotinib—CYP3A4—Cimetidine—obesity	0.00317	0.0104	CbGbCtD
Nilotinib—CYP3A4—Topiramate—obesity	0.00208	0.0068	CbGbCtD
Nilotinib—Imatinib—CA3—obesity	0.00169	0.765	CrCbGaD
Nilotinib—CDC42BPB—islet of Langerhans—obesity	0.000738	0.0114	CbGeAlD
Nilotinib—CDC42BPB—respiratory system—obesity	0.000697	0.0108	CbGeAlD
Nilotinib—MAPK8—islet of Langerhans—obesity	0.000668	0.0103	CbGeAlD
Nilotinib—CA9—gall bladder—obesity	0.000663	0.0103	CbGeAlD
Nilotinib—MAPK14—hindbrain—obesity	0.000656	0.0102	CbGeAlD
Nilotinib—MAPK8—respiratory system—obesity	0.00063	0.00977	CbGeAlD
Nilotinib—CDC42BPB—adrenal cortex—obesity	0.000585	0.00907	CbGeAlD
Nilotinib—TIE1—respiratory system—obesity	0.000547	0.00847	CbGeAlD
Nilotinib—CDC42BPB—cardiovascular system—obesity	0.000534	0.00827	CbGeAlD
Nilotinib—PDGFRA—gall bladder—obesity	0.000532	0.00824	CbGeAlD
Nilotinib—EPHB2—digestive system—obesity	0.000501	0.00777	CbGeAlD
Nilotinib—MAP2K5—hindbrain—obesity	0.000486	0.00753	CbGeAlD
Nilotinib—BLK—adrenal gland—obesity	0.000483	0.00749	CbGeAlD
Nilotinib—MAPK8—cardiovascular system—obesity	0.000483	0.00748	CbGeAlD
Nilotinib—MAPK11—adipose tissue—obesity	0.000475	0.00736	CbGeAlD
Nilotinib—CDC42BPB—pituitary gland—obesity	0.000473	0.00733	CbGeAlD
Nilotinib—CDC42BPB—adipose tissue—obesity	0.000471	0.0073	CbGeAlD
Nilotinib—TIE1—adrenal cortex—obesity	0.000459	0.00711	CbGeAlD
Nilotinib—EPHA3—adipose tissue—obesity	0.000446	0.00692	CbGeAlD
Nilotinib—CDC42BPB—digestive system—obesity	0.000443	0.00687	CbGeAlD
Nilotinib—CA9—islet of Langerhans—obesity	0.000435	0.00674	CbGeAlD
Nilotinib—FRK—endocrine gland—obesity	0.000434	0.00673	CbGeAlD
Nilotinib—KIT—hindbrain—obesity	0.000431	0.00668	CbGeAlD
Nilotinib—CA3—respiratory system—obesity	0.000429	0.00665	CbGeAlD
Nilotinib—MAPK8—pituitary gland—obesity	0.000428	0.00663	CbGeAlD
Nilotinib—MAPK11—adrenal gland—obesity	0.000426	0.0066	CbGeAlD
Nilotinib—MAPK8—adipose tissue—obesity	0.000426	0.0066	CbGeAlD
Nilotinib—KIT—gall bladder—obesity	0.000425	0.00659	CbGeAlD
Nilotinib—CDC42BPB—adrenal gland—obesity	0.000422	0.00655	CbGeAlD
Nilotinib—TIE1—cardiovascular system—obesity	0.000419	0.00649	CbGeAlD
Nilotinib—PDGFRB—gall bladder—obesity	0.000415	0.00643	CbGeAlD
Nilotinib—EPHB4—islet of Langerhans—obesity	0.000402	0.00623	CbGeAlD
Nilotinib—HCK—adrenal cortex—obesity	0.000401	0.00621	CbGeAlD
Nilotinib—MAPK8—digestive system—obesity	0.000401	0.00621	CbGeAlD
Nilotinib—MAPK14—respiratory system—obesity	0.0004	0.00621	CbGeAlD
Nilotinib—EPHA3—adrenal gland—obesity	0.0004	0.0062	CbGeAlD
Nilotinib—FGR—respiratory system—obesity	0.000399	0.00618	CbGeAlD
Nilotinib—Imatinib—SLC22A1—obesity	0.000397	0.18	CrCbGaD
Nilotinib—EPHA2—islet of Langerhans—obesity	0.000394	0.00611	CbGeAlD
Nilotinib—FRK—liver—obesity	0.000392	0.00607	CbGeAlD
Nilotinib—MAP4K1—adipose tissue—obesity	0.000387	0.006	CbGeAlD
Nilotinib—MAPK8—adrenal gland—obesity	0.000382	0.00592	CbGeAlD
Nilotinib—EPHB4—respiratory system—obesity	0.00038	0.00588	CbGeAlD
Nilotinib—ABL1—hindbrain—obesity	0.000375	0.00581	CbGeAlD
Nilotinib—EPHA2—respiratory system—obesity	0.000372	0.00577	CbGeAlD
Nilotinib—TIE1—adipose tissue—obesity	0.000369	0.00572	CbGeAlD
Nilotinib—EPHB6—islet of Langerhans—obesity	0.000368	0.0057	CbGeAlD
Nilotinib—CDC42BPB—endocrine gland—obesity	0.000366	0.00568	CbGeAlD
Nilotinib—TEK—respiratory system—obesity	0.000363	0.00563	CbGeAlD
Nilotinib—BRAF—pituitary gland—obesity	0.000355	0.00551	CbGeAlD
Nilotinib—BRAF—adipose tissue—obesity	0.000354	0.00549	CbGeAlD
Nilotinib—MAP4K1—adrenal gland—obesity	0.000347	0.00538	CbGeAlD
Nilotinib—MAPK8—endocrine gland—obesity	0.000331	0.00513	CbGeAlD
Nilotinib—EPHA6—endocrine gland—obesity	0.000331	0.00513	CbGeAlD
Nilotinib—TIE1—adrenal gland—obesity	0.000331	0.00513	CbGeAlD
Nilotinib—EPHB3—digestive system—obesity	0.000331	0.00512	CbGeAlD
Nilotinib—CDC42BPB—liver—obesity	0.00033	0.00512	CbGeAlD
Nilotinib—PDGFRA—respiratory system—obesity	0.000329	0.0051	CbGeAlD
Nilotinib—CA3—cardiovascular system—obesity	0.000329	0.00509	CbGeAlD
Nilotinib—HCK—pituitary gland—obesity	0.000324	0.00502	CbGeAlD
Nilotinib—HCK—adipose tissue—obesity	0.000323	0.005	CbGeAlD
Nilotinib—ABL2—pituitary gland—obesity	0.000322	0.00499	CbGeAlD
Nilotinib—ABL2—adipose tissue—obesity	0.000321	0.00497	CbGeAlD
Nilotinib—EPHB4—adrenal cortex—obesity	0.000319	0.00494	CbGeAlD
Nilotinib—BRAF—adrenal gland—obesity	0.000317	0.00492	CbGeAlD
Nilotinib—EPHB3—adrenal gland—obesity	0.000315	0.00488	CbGeAlD
Nilotinib—EPHA2—adrenal cortex—obesity	0.000313	0.00484	CbGeAlD
Nilotinib—CA4—hindbrain—obesity	0.000308	0.00477	CbGeAlD
Nilotinib—MAPK14—cardiovascular system—obesity	0.000307	0.00475	CbGeAlD
Nilotinib—LYN—endocrine gland—obesity	0.000306	0.00474	CbGeAlD
Nilotinib—FGR—cardiovascular system—obesity	0.000305	0.00473	CbGeAlD
Nilotinib—TEK—adrenal cortex—obesity	0.000305	0.00472	CbGeAlD
Nilotinib—HCK—digestive system—obesity	0.000304	0.00471	CbGeAlD
Nilotinib—CA12—respiratory system—obesity	0.000304	0.00471	CbGeAlD
Nilotinib—MAPK8—liver—obesity	0.000299	0.00463	CbGeAlD
Nilotinib—CA7—digestive system—obesity	0.000297	0.00461	CbGeAlD
Nilotinib—EPHA4—pituitary gland—obesity	0.000294	0.00456	CbGeAlD
Nilotinib—EPHA4—adipose tissue—obesity	0.000293	0.00455	CbGeAlD
Nilotinib—CA3—pituitary gland—obesity	0.000291	0.00451	CbGeAlD
Nilotinib—EPHB4—cardiovascular system—obesity	0.000291	0.00451	CbGeAlD
Nilotinib—CSF1R—respiratory system—obesity	0.00029	0.00449	CbGeAlD
Nilotinib—CA3—adipose tissue—obesity	0.00029	0.00449	CbGeAlD
Nilotinib—HCK—adrenal gland—obesity	0.000289	0.00449	CbGeAlD
Nilotinib—ABL2—adrenal gland—obesity	0.000288	0.00446	CbGeAlD
Nilotinib—EPHA2—cardiovascular system—obesity	0.000285	0.00442	CbGeAlD
Nilotinib—TEK—cardiovascular system—obesity	0.000278	0.00431	CbGeAlD
Nilotinib—LYN—liver—obesity	0.000276	0.00427	CbGeAlD
Nilotinib—PDGFRB—islet of Langerhans—obesity	0.000272	0.00422	CbGeAlD
Nilotinib—MAPK14—pituitary gland—obesity	0.000272	0.00421	CbGeAlD
Nilotinib—FGR—pituitary gland—obesity	0.00027	0.00419	CbGeAlD
Nilotinib—MAPK14—adipose tissue—obesity	0.00027	0.00419	CbGeAlD
Nilotinib—LCK—adipose tissue—obesity	0.000269	0.00417	CbGeAlD
Nilotinib—FGR—adipose tissue—obesity	0.000269	0.00417	CbGeAlD
Nilotinib—KIT—respiratory system—obesity	0.000263	0.00408	CbGeAlD
Nilotinib—EPHA4—adrenal gland—obesity	0.000263	0.00408	CbGeAlD
Nilotinib—CA9—digestive system—obesity	0.000261	0.00405	CbGeAlD
Nilotinib—TIE1—liver—obesity	0.000259	0.00401	CbGeAlD
Nilotinib—EPHB4—pituitary gland—obesity	0.000257	0.00399	CbGeAlD
Nilotinib—PDGFRB—respiratory system—obesity	0.000257	0.00398	CbGeAlD
Nilotinib—EPHB4—adipose tissue—obesity	0.000256	0.00397	CbGeAlD
Nilotinib—CA2—hindbrain—obesity	0.000255	0.00396	CbGeAlD
Nilotinib—MAPK14—digestive system—obesity	0.000255	0.00395	CbGeAlD
Nilotinib—FGR—digestive system—obesity	0.000254	0.00393	CbGeAlD
Nilotinib—EPHA2—pituitary gland—obesity	0.000253	0.00391	CbGeAlD
Nilotinib—PDGFRA—cardiovascular system—obesity	0.000252	0.00391	CbGeAlD
Nilotinib—CA2—gall bladder—obesity	0.000252	0.0039	CbGeAlD
Nilotinib—EPHA2—adipose tissue—obesity	0.000251	0.0039	CbGeAlD
Nilotinib—HCK—endocrine gland—obesity	0.000251	0.00389	CbGeAlD
Nilotinib—MAP2K5—adrenal cortex—obesity	0.000249	0.00386	CbGeAlD
Nilotinib—BRAF—liver—obesity	0.000248	0.00385	CbGeAlD
Nilotinib—TEK—pituitary gland—obesity	0.000246	0.00382	CbGeAlD
Nilotinib—TEK—adipose tissue—obesity	0.000245	0.0038	CbGeAlD
Nilotinib—CSF1R—adrenal cortex—obesity	0.000243	0.00377	CbGeAlD
Nilotinib—MAPK14—adrenal gland—obesity	0.000243	0.00376	CbGeAlD
Nilotinib—ABL1—islet of Langerhans—obesity	0.000243	0.00376	CbGeAlD
Nilotinib—FGR—adrenal gland—obesity	0.000242	0.00374	CbGeAlD
Nilotinib—LCK—adrenal gland—obesity	0.000242	0.00374	CbGeAlD
Nilotinib—EPHB4—digestive system—obesity	0.000241	0.00374	CbGeAlD
Nilotinib—CA1—respiratory system—obesity	0.000241	0.00373	CbGeAlD
Nilotinib—EPHA2—digestive system—obesity	0.000237	0.00367	CbGeAlD
Nilotinib—CA14—adrenal gland—obesity	0.000236	0.00366	CbGeAlD
Nilotinib—EPHB6—pituitary gland—obesity	0.000235	0.00365	CbGeAlD
Nilotinib—EPHB6—adipose tissue—obesity	0.000234	0.00363	CbGeAlD
Nilotinib—EPHB4—adrenal gland—obesity	0.00023	0.00356	CbGeAlD
Nilotinib—ABL1—respiratory system—obesity	0.000229	0.00355	CbGeAlD
Nilotinib—EPHA4—endocrine gland—obesity	0.000228	0.00354	CbGeAlD
Nilotinib—MAP2K5—cardiovascular system—obesity	0.000227	0.00352	CbGeAlD
Nilotinib—HCK—liver—obesity	0.000226	0.00351	CbGeAlD
Nilotinib—EPHA2—adrenal gland—obesity	0.000226	0.0035	CbGeAlD
Nilotinib—CA3—endocrine gland—obesity	0.000225	0.00349	CbGeAlD
Nilotinib—ABL2—liver—obesity	0.000225	0.00349	CbGeAlD
Nilotinib—PDGFRA—adipose tissue—obesity	0.000222	0.00344	CbGeAlD
Nilotinib—CSF1R—cardiovascular system—obesity	0.000222	0.00344	CbGeAlD
Nilotinib—TEK—adrenal gland—obesity	0.00022	0.00341	CbGeAlD
Nilotinib—CA9—endocrine gland—obesity	0.000216	0.00334	CbGeAlD
Nilotinib—PDGFRB—adrenal cortex—obesity	0.000216	0.00334	CbGeAlD
Nilotinib—MAPK14—endocrine gland—obesity	0.00021	0.00326	CbGeAlD
Nilotinib—EPHB6—adrenal gland—obesity	0.00021	0.00326	CbGeAlD
Nilotinib—FGR—endocrine gland—obesity	0.000209	0.00325	CbGeAlD
Nilotinib—PDGFRA—digestive system—obesity	0.000209	0.00324	CbGeAlD
Nilotinib—CA3—liver—obesity	0.000203	0.00315	CbGeAlD
Nilotinib—KIT—cardiovascular system—obesity	0.000202	0.00312	CbGeAlD
Nilotinib—MAP2K5—pituitary gland—obesity	0.000201	0.00312	CbGeAlD
Nilotinib—MAP2K5—adipose tissue—obesity	0.000201	0.00311	CbGeAlD
Nilotinib—UGT1A1—digestive system—obesity	0.0002	0.00309	CbGeAlD
Nilotinib—EPHB4—endocrine gland—obesity	0.000199	0.00309	CbGeAlD
Nilotinib—PDGFRA—adrenal gland—obesity	0.000199	0.00309	CbGeAlD
Nilotinib—CA4—islet of Langerhans—obesity	0.000199	0.00309	CbGeAlD
Nilotinib—PDGFRB—cardiovascular system—obesity	0.000197	0.00305	CbGeAlD
Nilotinib—CSF1R—pituitary gland—obesity	0.000196	0.00305	CbGeAlD
Nilotinib—CSF1R—adipose tissue—obesity	0.000196	0.00303	CbGeAlD
Nilotinib—EPHA2—endocrine gland—obesity	0.000196	0.00303	CbGeAlD
Nilotinib—CA12—digestive system—obesity	0.000193	0.00299	CbGeAlD
Nilotinib—ABL1—adrenal cortex—obesity	0.000192	0.00298	CbGeAlD
Nilotinib—TEK—endocrine gland—obesity	0.000191	0.00296	CbGeAlD
Nilotinib—MAPK14—liver—obesity	0.00019	0.00294	CbGeAlD
Nilotinib—FGR—liver—obesity	0.000189	0.00293	CbGeAlD
Nilotinib—LCK—liver—obesity	0.000189	0.00293	CbGeAlD
Nilotinib—CA4—respiratory system—obesity	0.000188	0.00291	CbGeAlD
Nilotinib—CA14—liver—obesity	0.000184	0.00286	CbGeAlD
Nilotinib—CA1—cardiovascular system—obesity	0.000184	0.00286	CbGeAlD
Nilotinib—CSF1R—digestive system—obesity	0.000184	0.00285	CbGeAlD
Nilotinib—MAP2K5—adrenal gland—obesity	0.00018	0.00279	CbGeAlD
Nilotinib—EPHB4—liver—obesity	0.00018	0.00279	CbGeAlD
Nilotinib—KIT—pituitary gland—obesity	0.000178	0.00277	CbGeAlD
Nilotinib—KIT—adipose tissue—obesity	0.000178	0.00275	CbGeAlD
Nilotinib—EPHA2—liver—obesity	0.000176	0.00273	CbGeAlD
Nilotinib—CSF1R—adrenal gland—obesity	0.000176	0.00272	CbGeAlD
Nilotinib—ABL1—cardiovascular system—obesity	0.000175	0.00272	CbGeAlD
Nilotinib—PDGFRB—pituitary gland—obesity	0.000174	0.0027	CbGeAlD
Nilotinib—PDGFRB—adipose tissue—obesity	0.000174	0.00269	CbGeAlD
Nilotinib—PDGFRA—endocrine gland—obesity	0.000173	0.00268	CbGeAlD
Nilotinib—TEK—liver—obesity	0.000172	0.00267	CbGeAlD
Nilotinib—KIT—digestive system—obesity	0.000167	0.00259	CbGeAlD
Nilotinib—CA2—islet of Langerhans—obesity	0.000165	0.00256	CbGeAlD
Nilotinib—UGT1A1—endocrine gland—obesity	0.000165	0.00256	CbGeAlD
Nilotinib—PDGFRB—digestive system—obesity	0.000163	0.00253	CbGeAlD
Nilotinib—CA1—adipose tissue—obesity	0.000163	0.00252	CbGeAlD
Nilotinib—CYP2D6—hindbrain—obesity	0.000162	0.00251	CbGeAlD
Nilotinib—CA12—endocrine gland—obesity	0.00016	0.00247	CbGeAlD
Nilotinib—KIT—adrenal gland—obesity	0.000159	0.00247	CbGeAlD
Nilotinib—MAP2K5—endocrine gland—obesity	0.000156	0.00242	CbGeAlD
Nilotinib—CA2—respiratory system—obesity	0.000156	0.00242	CbGeAlD
Nilotinib—PDGFRA—liver—obesity	0.000156	0.00242	CbGeAlD
Nilotinib—PDGFRB—adrenal gland—obesity	0.000156	0.00241	CbGeAlD
Nilotinib—ABL1—pituitary gland—obesity	0.000155	0.00241	CbGeAlD
Nilotinib—ABL1—adipose tissue—obesity	0.000155	0.0024	CbGeAlD
Nilotinib—CA1—digestive system—obesity	0.000153	0.00237	CbGeAlD
Nilotinib—CSF1R—endocrine gland—obesity	0.000152	0.00236	CbGeAlD
Nilotinib—UGT1A1—liver—obesity	0.000149	0.0023	CbGeAlD
Nilotinib—ABL1—digestive system—obesity	0.000146	0.00226	CbGeAlD
Nilotinib—CA4—cardiovascular system—obesity	0.000144	0.00223	CbGeAlD
Nilotinib—MAP2K5—liver—obesity	0.000141	0.00218	CbGeAlD
Nilotinib—ABL1—adrenal gland—obesity	0.000139	0.00215	CbGeAlD
Nilotinib—KIT—endocrine gland—obesity	0.000138	0.00214	CbGeAlD
Nilotinib—CSF1R—liver—obesity	0.000137	0.00213	CbGeAlD
Nilotinib—PDGFRB—endocrine gland—obesity	0.000135	0.00209	CbGeAlD
Nilotinib—CYP2B6—respiratory system—obesity	0.000133	0.00206	CbGeAlD
Nilotinib—CA2—adrenal cortex—obesity	0.000131	0.00203	CbGeAlD
Nilotinib—CA4—pituitary gland—obesity	0.000128	0.00198	CbGeAlD
Nilotinib—CA4—adipose tissue—obesity	0.000127	0.00197	CbGeAlD
Nilotinib—CA1—endocrine gland—obesity	0.000126	0.00196	CbGeAlD
Nilotinib—KIT—liver—obesity	0.000125	0.00193	CbGeAlD
Nilotinib—PDGFRB—liver—obesity	0.000122	0.00189	CbGeAlD
Nilotinib—ABCG2—adrenal cortex—obesity	0.000121	0.00188	CbGeAlD
Nilotinib—Imatinib—ALB—obesity	0.000121	0.0549	CrCbGaD
Nilotinib—ABL1—endocrine gland—obesity	0.00012	0.00186	CbGeAlD
Nilotinib—CA4—digestive system—obesity	0.00012	0.00185	CbGeAlD
Nilotinib—CA2—cardiovascular system—obesity	0.000119	0.00185	CbGeAlD
Nilotinib—CA1—liver—obesity	0.000114	0.00177	CbGeAlD
Nilotinib—CA4—adrenal gland—obesity	0.000114	0.00177	CbGeAlD
Nilotinib—CYP2B6—adrenal cortex—obesity	0.000112	0.00173	CbGeAlD
Nilotinib—ABL1—liver—obesity	0.000108	0.00168	CbGeAlD
Nilotinib—CA2—pituitary gland—obesity	0.000106	0.00164	CbGeAlD
Nilotinib—CA2—adipose tissue—obesity	0.000105	0.00163	CbGeAlD
Nilotinib—CYP2B6—cardiovascular system—obesity	0.000102	0.00158	CbGeAlD
Nilotinib—CYP2C9—cardiovascular system—obesity	0.000101	0.00157	CbGeAlD
Nilotinib—CYP2C8—pituitary gland—obesity	0.000101	0.00156	CbGeAlD
Nilotinib—CA2—digestive system—obesity	9.92e-05	0.00154	CbGeAlD
Nilotinib—CA4—endocrine gland—obesity	9.88e-05	0.00153	CbGeAlD
Nilotinib—ABCG2—pituitary gland—obesity	9.79e-05	0.00152	CbGeAlD
Nilotinib—ABCG2—adipose tissue—obesity	9.75e-05	0.00151	CbGeAlD
Nilotinib—CA2—adrenal gland—obesity	9.45e-05	0.00146	CbGeAlD
Nilotinib—ABCG2—adrenal gland—obesity	8.75e-05	0.00136	CbGeAlD
Nilotinib—CYP2B6—digestive system—obesity	8.47e-05	0.00131	CbGeAlD
Nilotinib—CYP2C9—digestive system—obesity	8.39e-05	0.0013	CbGeAlD
Nilotinib—CA2—endocrine gland—obesity	8.19e-05	0.00127	CbGeAlD
Nilotinib—CYP2B6—adrenal gland—obesity	8.07e-05	0.00125	CbGeAlD
Nilotinib—CYP2C8—endocrine gland—obesity	7.8e-05	0.00121	CbGeAlD
Nilotinib—Discomfort—Orlistat—obesity	7.65e-05	0.000685	CcSEcCtD
Nilotinib—Blood creatinine increased—Topiramate—obesity	7.6e-05	0.000681	CcSEcCtD
Nilotinib—Hypertension—Sibutramine—obesity	7.6e-05	0.00068	CcSEcCtD
Nilotinib—Dry mouth—Orlistat—obesity	7.57e-05	0.000678	CcSEcCtD
Nilotinib—Flatulence—Bupropion—obesity	7.56e-05	0.000677	CcSEcCtD
Nilotinib—Dehydration—Topiramate—obesity	7.55e-05	0.000676	CcSEcCtD
Nilotinib—ABCB1—islet of Langerhans—obesity	7.54e-05	0.00117	CbGeAlD
Nilotinib—Dysgeusia—Bupropion—obesity	7.51e-05	0.000673	CcSEcCtD
Nilotinib—Chest pain—Sibutramine—obesity	7.49e-05	0.000671	CcSEcCtD
Nilotinib—Arthralgia—Sibutramine—obesity	7.49e-05	0.000671	CcSEcCtD
Nilotinib—Myalgia—Sibutramine—obesity	7.49e-05	0.000671	CcSEcCtD
Nilotinib—Anxiety—Sibutramine—obesity	7.46e-05	0.000669	CcSEcCtD
Nilotinib—Oedema—Orlistat—obesity	7.42e-05	0.000665	CcSEcCtD
Nilotinib—Back pain—Bupropion—obesity	7.42e-05	0.000665	CcSEcCtD
Nilotinib—Abdominal pain upper—Topiramate—obesity	7.41e-05	0.000664	CcSEcCtD
Nilotinib—Discomfort—Sibutramine—obesity	7.4e-05	0.000663	CcSEcCtD
Nilotinib—CA2—liver—obesity	7.39e-05	0.00114	CbGeAlD
Nilotinib—Hypokalaemia—Topiramate—obesity	7.39e-05	0.000662	CcSEcCtD
Nilotinib—Muscle spasms—Bupropion—obesity	7.37e-05	0.000661	CcSEcCtD
Nilotinib—Infection—Orlistat—obesity	7.37e-05	0.00066	CcSEcCtD
Nilotinib—Breast disorder—Topiramate—obesity	7.33e-05	0.000657	CcSEcCtD
Nilotinib—Dry mouth—Sibutramine—obesity	7.33e-05	0.000656	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Topiramate—obesity	7.31e-05	0.000655	CcSEcCtD
Nilotinib—Nervous system disorder—Orlistat—obesity	7.28e-05	0.000652	CcSEcCtD
Nilotinib—Nasopharyngitis—Topiramate—obesity	7.26e-05	0.00065	CcSEcCtD
Nilotinib—Confusional state—Sibutramine—obesity	7.24e-05	0.000649	CcSEcCtD
Nilotinib—Vision blurred—Bupropion—obesity	7.23e-05	0.000648	CcSEcCtD
Nilotinib—Skin disorder—Orlistat—obesity	7.21e-05	0.000646	CcSEcCtD
Nilotinib—Tremor—Bupropion—obesity	7.19e-05	0.000644	CcSEcCtD
Nilotinib—Gastritis—Topiramate—obesity	7.18e-05	0.000643	CcSEcCtD
Nilotinib—Oedema—Sibutramine—obesity	7.18e-05	0.000643	CcSEcCtD
Nilotinib—Hyperhidrosis—Orlistat—obesity	7.17e-05	0.000643	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Topiramate—obesity	7.16e-05	0.000641	CcSEcCtD
Nilotinib—Muscular weakness—Topiramate—obesity	7.16e-05	0.000641	CcSEcCtD
Nilotinib—Infection—Sibutramine—obesity	7.13e-05	0.000639	CcSEcCtD
Nilotinib—ABCB1—respiratory system—obesity	7.12e-05	0.0011	CbGeAlD
Nilotinib—Ill-defined disorder—Bupropion—obesity	7.12e-05	0.000638	CcSEcCtD
Nilotinib—Anaemia—Bupropion—obesity	7.09e-05	0.000635	CcSEcCtD
Nilotinib—Shock—Sibutramine—obesity	7.06e-05	0.000633	CcSEcCtD
Nilotinib—Abdominal distension—Topiramate—obesity	7.06e-05	0.000632	CcSEcCtD
Nilotinib—CYP2C8—liver—obesity	7.04e-05	0.00109	CbGeAlD
Nilotinib—Thrombocytopenia—Sibutramine—obesity	7.03e-05	0.00063	CcSEcCtD
Nilotinib—Tachycardia—Sibutramine—obesity	7.01e-05	0.000628	CcSEcCtD
Nilotinib—CYP2B6—endocrine gland—obesity	7e-05	0.00108	CbGeAlD
Nilotinib—Skin disorder—Sibutramine—obesity	6.97e-05	0.000625	CcSEcCtD
Nilotinib—Eosinophilia—Topiramate—obesity	6.94e-05	0.000622	CcSEcCtD
Nilotinib—Hyperhidrosis—Sibutramine—obesity	6.94e-05	0.000622	CcSEcCtD
Nilotinib—CYP2C9—endocrine gland—obesity	6.93e-05	0.00107	CbGeAlD
Nilotinib—Malaise—Bupropion—obesity	6.92e-05	0.00062	CcSEcCtD
Nilotinib—Vertigo—Bupropion—obesity	6.89e-05	0.000617	CcSEcCtD
Nilotinib—Syncope—Bupropion—obesity	6.88e-05	0.000616	CcSEcCtD
Nilotinib—Pancreatitis—Topiramate—obesity	6.88e-05	0.000616	CcSEcCtD
Nilotinib—Leukopenia—Bupropion—obesity	6.87e-05	0.000615	CcSEcCtD
Nilotinib—Anorexia—Sibutramine—obesity	6.84e-05	0.000613	CcSEcCtD
Nilotinib—ABCG2—liver—obesity	6.84e-05	0.00106	CbGeAlD
Nilotinib—Angina pectoris—Topiramate—obesity	6.83e-05	0.000612	CcSEcCtD
Nilotinib—Palpitations—Bupropion—obesity	6.78e-05	0.000607	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Orlistat—obesity	6.76e-05	0.000606	CcSEcCtD
Nilotinib—Bronchitis—Topiramate—obesity	6.74e-05	0.000604	CcSEcCtD
Nilotinib—Loss of consciousness—Bupropion—obesity	6.74e-05	0.000604	CcSEcCtD
Nilotinib—Abdominal discomfort—Topiramate—obesity	6.72e-05	0.000602	CcSEcCtD
Nilotinib—Insomnia—Orlistat—obesity	6.71e-05	0.000601	CcSEcCtD
Nilotinib—Hypotension—Sibutramine—obesity	6.71e-05	0.000601	CcSEcCtD
Nilotinib—Cough—Bupropion—obesity	6.69e-05	0.0006	CcSEcCtD
Nilotinib—Paraesthesia—Orlistat—obesity	6.66e-05	0.000597	CcSEcCtD
Nilotinib—Pancytopenia—Topiramate—obesity	6.66e-05	0.000597	CcSEcCtD
Nilotinib—Hypertension—Bupropion—obesity	6.62e-05	0.000593	CcSEcCtD
Nilotinib—Neutropenia—Topiramate—obesity	6.56e-05	0.000587	CcSEcCtD
Nilotinib—Dysuria—Topiramate—obesity	6.56e-05	0.000587	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Sibutramine—obesity	6.54e-05	0.000586	CcSEcCtD
Nilotinib—Dyspepsia—Orlistat—obesity	6.53e-05	0.000585	CcSEcCtD
Nilotinib—Arthralgia—Bupropion—obesity	6.53e-05	0.000585	CcSEcCtD
Nilotinib—Chest pain—Bupropion—obesity	6.53e-05	0.000585	CcSEcCtD
Nilotinib—Myalgia—Bupropion—obesity	6.53e-05	0.000585	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Topiramate—obesity	6.52e-05	0.000584	CcSEcCtD
Nilotinib—Anxiety—Bupropion—obesity	6.51e-05	0.000583	CcSEcCtD
Nilotinib—Insomnia—Sibutramine—obesity	6.49e-05	0.000582	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	6.49e-05	0.000581	CcSEcCtD
Nilotinib—Pollakiuria—Topiramate—obesity	6.48e-05	0.00058	CcSEcCtD
Nilotinib—Erectile dysfunction—Topiramate—obesity	6.46e-05	0.000579	CcSEcCtD
Nilotinib—Discomfort—Bupropion—obesity	6.45e-05	0.000578	CcSEcCtD
Nilotinib—Decreased appetite—Orlistat—obesity	6.45e-05	0.000578	CcSEcCtD
Nilotinib—Paraesthesia—Sibutramine—obesity	6.45e-05	0.000578	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Orlistat—obesity	6.41e-05	0.000574	CcSEcCtD
Nilotinib—Dyspnoea—Sibutramine—obesity	6.4e-05	0.000573	CcSEcCtD
Nilotinib—Photosensitivity reaction—Topiramate—obesity	6.4e-05	0.000573	CcSEcCtD
Nilotinib—Fatigue—Orlistat—obesity	6.4e-05	0.000573	CcSEcCtD
Nilotinib—CYP3A4—digestive system—obesity	6.4e-05	0.000991	CbGeAlD
Nilotinib—Dry mouth—Bupropion—obesity	6.39e-05	0.000572	CcSEcCtD
Nilotinib—Weight increased—Topiramate—obesity	6.38e-05	0.000572	CcSEcCtD
Nilotinib—Weight decreased—Topiramate—obesity	6.35e-05	0.000568	CcSEcCtD
Nilotinib—Pain—Orlistat—obesity	6.34e-05	0.000568	CcSEcCtD
Nilotinib—Hyperglycaemia—Topiramate—obesity	6.33e-05	0.000567	CcSEcCtD
Nilotinib—Dyspepsia—Sibutramine—obesity	6.32e-05	0.000566	CcSEcCtD
Nilotinib—Confusional state—Bupropion—obesity	6.31e-05	0.000565	CcSEcCtD
Nilotinib—CYP2B6—liver—obesity	6.31e-05	0.000978	CbGeAlD
Nilotinib—CYP2D6—digestive system—obesity	6.29e-05	0.000976	CbGeAlD
Nilotinib—Pneumonia—Topiramate—obesity	6.29e-05	0.000563	CcSEcCtD
Nilotinib—Oedema—Bupropion—obesity	6.26e-05	0.000561	CcSEcCtD
Nilotinib—Infestation—Topiramate—obesity	6.25e-05	0.00056	CcSEcCtD
Nilotinib—Infestation NOS—Topiramate—obesity	6.25e-05	0.00056	CcSEcCtD
Nilotinib—CYP2C9—liver—obesity	6.25e-05	0.000969	CbGeAlD
Nilotinib—Decreased appetite—Sibutramine—obesity	6.24e-05	0.000559	CcSEcCtD
Nilotinib—Infection—Bupropion—obesity	6.22e-05	0.000557	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Sibutramine—obesity	6.2e-05	0.000555	CcSEcCtD
Nilotinib—Shock—Bupropion—obesity	6.16e-05	0.000552	CcSEcCtD
Nilotinib—Renal failure—Topiramate—obesity	6.15e-05	0.000551	CcSEcCtD
Nilotinib—Pain—Sibutramine—obesity	6.14e-05	0.00055	CcSEcCtD
Nilotinib—Constipation—Sibutramine—obesity	6.14e-05	0.00055	CcSEcCtD
Nilotinib—Nervous system disorder—Bupropion—obesity	6.14e-05	0.00055	CcSEcCtD
Nilotinib—Neuropathy peripheral—Topiramate—obesity	6.13e-05	0.000549	CcSEcCtD
Nilotinib—Thrombocytopenia—Bupropion—obesity	6.13e-05	0.000549	CcSEcCtD
Nilotinib—Feeling abnormal—Orlistat—obesity	6.11e-05	0.000548	CcSEcCtD
Nilotinib—Tachycardia—Bupropion—obesity	6.11e-05	0.000547	CcSEcCtD
Nilotinib—Stomatitis—Topiramate—obesity	6.1e-05	0.000546	CcSEcCtD
Nilotinib—Skin disorder—Bupropion—obesity	6.08e-05	0.000545	CcSEcCtD
Nilotinib—Conjunctivitis—Topiramate—obesity	6.08e-05	0.000545	CcSEcCtD
Nilotinib—Urinary tract infection—Topiramate—obesity	6.08e-05	0.000545	CcSEcCtD
Nilotinib—Gastrointestinal pain—Orlistat—obesity	6.07e-05	0.000544	CcSEcCtD
Nilotinib—Hyperhidrosis—Bupropion—obesity	6.05e-05	0.000542	CcSEcCtD
Nilotinib—ABCB1—adrenal cortex—obesity	5.98e-05	0.000926	CbGeAlD
Nilotinib—Anorexia—Bupropion—obesity	5.97e-05	0.000535	CcSEcCtD
Nilotinib—Haematuria—Topiramate—obesity	5.96e-05	0.000534	CcSEcCtD
Nilotinib—Feeling abnormal—Sibutramine—obesity	5.92e-05	0.00053	CcSEcCtD
Nilotinib—Epistaxis—Topiramate—obesity	5.9e-05	0.000528	CcSEcCtD
Nilotinib—Urticaria—Orlistat—obesity	5.89e-05	0.000528	CcSEcCtD
Nilotinib—Gastrointestinal pain—Sibutramine—obesity	5.87e-05	0.000526	CcSEcCtD
Nilotinib—Body temperature increased—Orlistat—obesity	5.87e-05	0.000525	CcSEcCtD
Nilotinib—Abdominal pain—Orlistat—obesity	5.87e-05	0.000525	CcSEcCtD
Nilotinib—Hypotension—Bupropion—obesity	5.85e-05	0.000524	CcSEcCtD
Nilotinib—Bradycardia—Topiramate—obesity	5.71e-05	0.000512	CcSEcCtD
Nilotinib—Urticaria—Sibutramine—obesity	5.7e-05	0.000511	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Bupropion—obesity	5.7e-05	0.000511	CcSEcCtD
Nilotinib—Body temperature increased—Sibutramine—obesity	5.68e-05	0.000509	CcSEcCtD
Nilotinib—Abdominal pain—Sibutramine—obesity	5.68e-05	0.000509	CcSEcCtD
Nilotinib—Insomnia—Bupropion—obesity	5.66e-05	0.000507	CcSEcCtD
Nilotinib—Haemoglobin—Topiramate—obesity	5.64e-05	0.000505	CcSEcCtD
Nilotinib—Rhinitis—Topiramate—obesity	5.63e-05	0.000504	CcSEcCtD
Nilotinib—Paraesthesia—Bupropion—obesity	5.62e-05	0.000504	CcSEcCtD
Nilotinib—Hepatitis—Topiramate—obesity	5.61e-05	0.000503	CcSEcCtD
Nilotinib—Haemorrhage—Topiramate—obesity	5.61e-05	0.000503	CcSEcCtD
Nilotinib—Hypoaesthesia—Topiramate—obesity	5.59e-05	0.0005	CcSEcCtD
Nilotinib—Dyspnoea—Bupropion—obesity	5.58e-05	0.0005	CcSEcCtD
Nilotinib—Pharyngitis—Topiramate—obesity	5.57e-05	0.000499	CcSEcCtD
Nilotinib—Urinary tract disorder—Topiramate—obesity	5.54e-05	0.000497	CcSEcCtD
Nilotinib—Oedema peripheral—Topiramate—obesity	5.53e-05	0.000495	CcSEcCtD
Nilotinib—Connective tissue disorder—Topiramate—obesity	5.52e-05	0.000494	CcSEcCtD
Nilotinib—Dyspepsia—Bupropion—obesity	5.51e-05	0.000494	CcSEcCtD
Nilotinib—Urethral disorder—Topiramate—obesity	5.5e-05	0.000493	CcSEcCtD
Nilotinib—Hypersensitivity—Orlistat—obesity	5.47e-05	0.00049	CcSEcCtD
Nilotinib—ABCB1—cardiovascular system—obesity	5.45e-05	0.000845	CbGeAlD
Nilotinib—Decreased appetite—Bupropion—obesity	5.44e-05	0.000487	CcSEcCtD
Nilotinib—Visual impairment—Topiramate—obesity	5.41e-05	0.000485	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Bupropion—obesity	5.4e-05	0.000484	CcSEcCtD
Nilotinib—Fatigue—Bupropion—obesity	5.4e-05	0.000483	CcSEcCtD
Nilotinib—Constipation—Bupropion—obesity	5.35e-05	0.00048	CcSEcCtD
Nilotinib—Pain—Bupropion—obesity	5.35e-05	0.00048	CcSEcCtD
Nilotinib—Asthenia—Orlistat—obesity	5.32e-05	0.000477	CcSEcCtD
Nilotinib—Erythema multiforme—Topiramate—obesity	5.31e-05	0.000475	CcSEcCtD
Nilotinib—Hypersensitivity—Sibutramine—obesity	5.29e-05	0.000474	CcSEcCtD
Nilotinib—CYP3A4—endocrine gland—obesity	5.29e-05	0.000819	CbGeAlD
Nilotinib—Pruritus—Orlistat—obesity	5.25e-05	0.00047	CcSEcCtD
Nilotinib—Eye disorder—Topiramate—obesity	5.25e-05	0.00047	CcSEcCtD
Nilotinib—Tinnitus—Topiramate—obesity	5.23e-05	0.000469	CcSEcCtD
Nilotinib—Cardiac disorder—Topiramate—obesity	5.21e-05	0.000467	CcSEcCtD
Nilotinib—Flushing—Topiramate—obesity	5.21e-05	0.000467	CcSEcCtD
Nilotinib—CYP2D6—endocrine gland—obesity	5.2e-05	0.000806	CbGeAlD
Nilotinib—Feeling abnormal—Bupropion—obesity	5.16e-05	0.000462	CcSEcCtD
Nilotinib—Asthenia—Sibutramine—obesity	5.15e-05	0.000462	CcSEcCtD
Nilotinib—Gastrointestinal pain—Bupropion—obesity	5.12e-05	0.000459	CcSEcCtD
Nilotinib—Angiopathy—Topiramate—obesity	5.09e-05	0.000456	CcSEcCtD
Nilotinib—Pruritus—Sibutramine—obesity	5.08e-05	0.000455	CcSEcCtD
Nilotinib—Diarrhoea—Orlistat—obesity	5.08e-05	0.000455	CcSEcCtD
Nilotinib—Immune system disorder—Topiramate—obesity	5.07e-05	0.000454	CcSEcCtD
Nilotinib—Mediastinal disorder—Topiramate—obesity	5.06e-05	0.000453	CcSEcCtD
Nilotinib—Chills—Topiramate—obesity	5.04e-05	0.000451	CcSEcCtD
Nilotinib—Urticaria—Bupropion—obesity	4.97e-05	0.000446	CcSEcCtD
Nilotinib—Alopecia—Topiramate—obesity	4.96e-05	0.000444	CcSEcCtD
Nilotinib—Body temperature increased—Bupropion—obesity	4.95e-05	0.000443	CcSEcCtD
Nilotinib—Abdominal pain—Bupropion—obesity	4.95e-05	0.000443	CcSEcCtD
Nilotinib—Mental disorder—Topiramate—obesity	4.92e-05	0.000441	CcSEcCtD
Nilotinib—Diarrhoea—Sibutramine—obesity	4.91e-05	0.00044	CcSEcCtD
Nilotinib—Dizziness—Orlistat—obesity	4.91e-05	0.00044	CcSEcCtD
Nilotinib—Malnutrition—Topiramate—obesity	4.89e-05	0.000438	CcSEcCtD
Nilotinib—Erythema—Topiramate—obesity	4.89e-05	0.000438	CcSEcCtD
Nilotinib—ABCB1—pituitary gland—obesity	4.83e-05	0.000748	CbGeAlD
Nilotinib—Flatulence—Topiramate—obesity	4.82e-05	0.000431	CcSEcCtD
Nilotinib—ABCB1—adipose tissue—obesity	4.81e-05	0.000745	CbGeAlD
Nilotinib—Dysgeusia—Topiramate—obesity	4.79e-05	0.000429	CcSEcCtD
Nilotinib—CYP3A4—liver—obesity	4.77e-05	0.000739	CbGeAlD
Nilotinib—Dizziness—Sibutramine—obesity	4.75e-05	0.000425	CcSEcCtD
Nilotinib—Back pain—Topiramate—obesity	4.73e-05	0.000423	CcSEcCtD
Nilotinib—Vomiting—Orlistat—obesity	4.72e-05	0.000423	CcSEcCtD
Nilotinib—Muscle spasms—Topiramate—obesity	4.7e-05	0.000421	CcSEcCtD
Nilotinib—CYP2D6—liver—obesity	4.69e-05	0.000727	CbGeAlD
Nilotinib—Rash—Orlistat—obesity	4.68e-05	0.000419	CcSEcCtD
Nilotinib—Dermatitis—Orlistat—obesity	4.67e-05	0.000419	CcSEcCtD
Nilotinib—Headache—Orlistat—obesity	4.65e-05	0.000416	CcSEcCtD
Nilotinib—Hypersensitivity—Bupropion—obesity	4.61e-05	0.000413	CcSEcCtD
Nilotinib—Vision blurred—Topiramate—obesity	4.61e-05	0.000413	CcSEcCtD
Nilotinib—Tremor—Topiramate—obesity	4.58e-05	0.00041	CcSEcCtD
Nilotinib—Vomiting—Sibutramine—obesity	4.57e-05	0.000409	CcSEcCtD
Nilotinib—Ill-defined disorder—Topiramate—obesity	4.53e-05	0.000406	CcSEcCtD
Nilotinib—ABCB1—digestive system—obesity	4.53e-05	0.000702	CbGeAlD
Nilotinib—Rash—Sibutramine—obesity	4.53e-05	0.000406	CcSEcCtD
Nilotinib—Dermatitis—Sibutramine—obesity	4.52e-05	0.000405	CcSEcCtD
Nilotinib—Anaemia—Topiramate—obesity	4.52e-05	0.000405	CcSEcCtD
Nilotinib—Headache—Sibutramine—obesity	4.5e-05	0.000403	CcSEcCtD
Nilotinib—Asthenia—Bupropion—obesity	4.49e-05	0.000402	CcSEcCtD
Nilotinib—Pruritus—Bupropion—obesity	4.43e-05	0.000397	CcSEcCtD
Nilotinib—Nausea—Orlistat—obesity	4.41e-05	0.000395	CcSEcCtD
Nilotinib—Malaise—Topiramate—obesity	4.41e-05	0.000395	CcSEcCtD
Nilotinib—Vertigo—Topiramate—obesity	4.39e-05	0.000393	CcSEcCtD
Nilotinib—Syncope—Topiramate—obesity	4.38e-05	0.000393	CcSEcCtD
Nilotinib—Leukopenia—Topiramate—obesity	4.37e-05	0.000392	CcSEcCtD
Nilotinib—Palpitations—Topiramate—obesity	4.32e-05	0.000387	CcSEcCtD
Nilotinib—ABCB1—adrenal gland—obesity	4.31e-05	0.000669	CbGeAlD
Nilotinib—Loss of consciousness—Topiramate—obesity	4.3e-05	0.000385	CcSEcCtD
Nilotinib—Diarrhoea—Bupropion—obesity	4.28e-05	0.000384	CcSEcCtD
Nilotinib—Nausea—Sibutramine—obesity	4.27e-05	0.000382	CcSEcCtD
Nilotinib—Cough—Topiramate—obesity	4.26e-05	0.000382	CcSEcCtD
Nilotinib—Hypertension—Topiramate—obesity	4.22e-05	0.000378	CcSEcCtD
Nilotinib—Chest pain—Topiramate—obesity	4.16e-05	0.000373	CcSEcCtD
Nilotinib—Myalgia—Topiramate—obesity	4.16e-05	0.000373	CcSEcCtD
Nilotinib—Arthralgia—Topiramate—obesity	4.16e-05	0.000373	CcSEcCtD
Nilotinib—Anxiety—Topiramate—obesity	4.15e-05	0.000371	CcSEcCtD
Nilotinib—Dizziness—Bupropion—obesity	4.14e-05	0.000371	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	4.13e-05	0.00037	CcSEcCtD
Nilotinib—Discomfort—Topiramate—obesity	4.11e-05	0.000368	CcSEcCtD
Nilotinib—Dry mouth—Topiramate—obesity	4.07e-05	0.000364	CcSEcCtD
Nilotinib—Confusional state—Topiramate—obesity	4.02e-05	0.00036	CcSEcCtD
Nilotinib—Oedema—Topiramate—obesity	3.99e-05	0.000357	CcSEcCtD
Nilotinib—Vomiting—Bupropion—obesity	3.98e-05	0.000357	CcSEcCtD
Nilotinib—Infection—Topiramate—obesity	3.96e-05	0.000355	CcSEcCtD
Nilotinib—Rash—Bupropion—obesity	3.95e-05	0.000354	CcSEcCtD
Nilotinib—Dermatitis—Bupropion—obesity	3.94e-05	0.000353	CcSEcCtD
Nilotinib—Shock—Topiramate—obesity	3.92e-05	0.000352	CcSEcCtD
Nilotinib—Headache—Bupropion—obesity	3.92e-05	0.000351	CcSEcCtD
Nilotinib—Nervous system disorder—Topiramate—obesity	3.91e-05	0.00035	CcSEcCtD
Nilotinib—Thrombocytopenia—Topiramate—obesity	3.9e-05	0.00035	CcSEcCtD
Nilotinib—Tachycardia—Topiramate—obesity	3.89e-05	0.000349	CcSEcCtD
Nilotinib—Skin disorder—Topiramate—obesity	3.87e-05	0.000347	CcSEcCtD
Nilotinib—Hyperhidrosis—Topiramate—obesity	3.86e-05	0.000345	CcSEcCtD
Nilotinib—Anorexia—Topiramate—obesity	3.8e-05	0.000341	CcSEcCtD
Nilotinib—ABCB1—endocrine gland—obesity	3.74e-05	0.00058	CbGeAlD
Nilotinib—Hypotension—Topiramate—obesity	3.73e-05	0.000334	CcSEcCtD
Nilotinib—Nausea—Bupropion—obesity	3.72e-05	0.000333	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Topiramate—obesity	3.63e-05	0.000326	CcSEcCtD
Nilotinib—Insomnia—Topiramate—obesity	3.61e-05	0.000323	CcSEcCtD
Nilotinib—Paraesthesia—Topiramate—obesity	3.58e-05	0.000321	CcSEcCtD
Nilotinib—Dyspnoea—Topiramate—obesity	3.56e-05	0.000319	CcSEcCtD
Nilotinib—Dyspepsia—Topiramate—obesity	3.51e-05	0.000314	CcSEcCtD
Nilotinib—Decreased appetite—Topiramate—obesity	3.47e-05	0.000311	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Topiramate—obesity	3.44e-05	0.000308	CcSEcCtD
Nilotinib—Fatigue—Topiramate—obesity	3.44e-05	0.000308	CcSEcCtD
Nilotinib—Constipation—Topiramate—obesity	3.41e-05	0.000306	CcSEcCtD
Nilotinib—Pain—Topiramate—obesity	3.41e-05	0.000306	CcSEcCtD
Nilotinib—ABCB1—liver—obesity	3.37e-05	0.000523	CbGeAlD
Nilotinib—Feeling abnormal—Topiramate—obesity	3.29e-05	0.000294	CcSEcCtD
Nilotinib—Gastrointestinal pain—Topiramate—obesity	3.26e-05	0.000292	CcSEcCtD
Nilotinib—Urticaria—Topiramate—obesity	3.17e-05	0.000284	CcSEcCtD
Nilotinib—Abdominal pain—Topiramate—obesity	3.15e-05	0.000282	CcSEcCtD
Nilotinib—Body temperature increased—Topiramate—obesity	3.15e-05	0.000282	CcSEcCtD
Nilotinib—Hypersensitivity—Topiramate—obesity	2.94e-05	0.000263	CcSEcCtD
Nilotinib—Asthenia—Topiramate—obesity	2.86e-05	0.000256	CcSEcCtD
Nilotinib—Pruritus—Topiramate—obesity	2.82e-05	0.000253	CcSEcCtD
Nilotinib—Diarrhoea—Topiramate—obesity	2.73e-05	0.000244	CcSEcCtD
Nilotinib—Dizziness—Topiramate—obesity	2.64e-05	0.000236	CcSEcCtD
Nilotinib—Vomiting—Topiramate—obesity	2.54e-05	0.000227	CcSEcCtD
Nilotinib—Rash—Topiramate—obesity	2.51e-05	0.000225	CcSEcCtD
Nilotinib—Dermatitis—Topiramate—obesity	2.51e-05	0.000225	CcSEcCtD
Nilotinib—Headache—Topiramate—obesity	2.5e-05	0.000224	CcSEcCtD
Nilotinib—Nausea—Topiramate—obesity	2.37e-05	0.000212	CcSEcCtD
Nilotinib—CYP2D6—Metabolism—COMT—obesity	5.5e-07	4.36e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOB—obesity	5.49e-07	4.35e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—obesity	5.48e-07	4.34e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—obesity	5.46e-07	4.33e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—obesity	5.46e-07	4.33e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—COMT—obesity	5.45e-07	4.33e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CPT1A—obesity	5.43e-07	4.31e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GNB3—obesity	5.42e-07	4.3e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARGC1A—obesity	5.42e-07	4.3e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—obesity	5.42e-07	4.3e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HMOX1—obesity	5.4e-07	4.28e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARGC1A—obesity	5.38e-07	4.27e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GNB3—obesity	5.38e-07	4.27e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CG—obesity	5.38e-07	4.26e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HMOX1—obesity	5.35e-07	4.25e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TYK2—obesity	5.35e-07	4.25e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—obesity	5.35e-07	4.25e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—obesity	5.32e-07	4.22e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NAMPT—obesity	5.32e-07	4.22e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARA—obesity	5.31e-07	4.22e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RHOA—obesity	5.31e-07	4.21e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LIPC—obesity	5.29e-07	4.2e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCK—obesity	5.29e-07	4.2e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—obesity	5.29e-07	4.2e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GNAS—obesity	5.28e-07	4.19e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—obesity	5.26e-07	4.17e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOC3—obesity	5.26e-07	4.17e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—obesity	5.25e-07	4.17e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3R1—obesity	5.25e-07	4.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—obesity	5.25e-07	4.17e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—LPL—obesity	5.24e-07	4.16e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GNAS—obesity	5.24e-07	4.15e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—obesity	5.19e-07	4.12e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—obesity	5.18e-07	4.11e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOB—obesity	5.17e-07	4.1e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—obesity	5.17e-07	4.1e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—obesity	5.17e-07	4.1e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AGT—obesity	5.15e-07	4.08e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—obesity	5.14e-07	4.08e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOB—obesity	5.13e-07	4.07e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—obesity	5.12e-07	4.06e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GPX1—obesity	5.11e-07	4.06e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK8—obesity	5.11e-07	4.05e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CETP—obesity	5.1e-07	4.05e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—obesity	5.09e-07	4.04e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—INS—obesity	5.09e-07	4.04e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—obesity	5.08e-07	4.03e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—obesity	5.06e-07	4.02e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SDC1—obesity	5.05e-07	4e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—obesity	5.05e-07	4e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—obesity	5.04e-07	4e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—obesity	5.04e-07	4e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK8—obesity	5e-07	3.97e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CAV1—obesity	5e-07	3.96e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOA1—obesity	4.98e-07	3.95e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CD36—obesity	4.98e-07	3.95e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—obesity	4.97e-07	3.95e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKR1C3—obesity	4.97e-07	3.94e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—obesity	4.96e-07	3.94e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—obesity	4.94e-07	3.92e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—LPL—obesity	4.94e-07	3.92e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—obesity	4.92e-07	3.9e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—obesity	4.91e-07	3.9e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—LPL—obesity	4.9e-07	3.88e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SCARB1—obesity	4.89e-07	3.88e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—obesity	4.88e-07	3.87e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MTOR—obesity	4.85e-07	3.85e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CB—obesity	4.85e-07	3.85e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GPX1—obesity	4.82e-07	3.82e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—obesity	4.82e-07	3.82e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—obesity	4.81e-07	3.81e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—obesity	4.79e-07	3.8e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GPX1—obesity	4.78e-07	3.79e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—obesity	4.77e-07	3.79e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—obesity	4.77e-07	3.78e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—obesity	4.75e-07	3.77e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SREBF1—obesity	4.75e-07	3.76e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK8—obesity	4.74e-07	3.76e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CD—obesity	4.73e-07	3.75e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—obesity	4.72e-07	3.74e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CD36—obesity	4.69e-07	3.72e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—obesity	4.68e-07	3.72e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—obesity	4.67e-07	3.71e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—obesity	4.67e-07	3.71e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—obesity	4.66e-07	3.7e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—obesity	4.66e-07	3.7e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—obesity	4.65e-07	3.69e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CD36—obesity	4.65e-07	3.69e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARA—obesity	4.63e-07	3.67e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GOT2—obesity	4.62e-07	3.66e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—obesity	4.57e-07	3.63e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—obesity	4.57e-07	3.63e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—obesity	4.56e-07	3.62e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CG—obesity	4.55e-07	3.61e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—obesity	4.54e-07	3.6e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—FASN—obesity	4.52e-07	3.58e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—BCHE—obesity	4.5e-07	3.57e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AGT—obesity	4.48e-07	3.56e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3R1—obesity	4.46e-07	3.54e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—obesity	4.46e-07	3.54e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—obesity	4.45e-07	3.53e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—obesity	4.41e-07	3.5e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—obesity	4.39e-07	3.48e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—obesity	4.39e-07	3.48e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARA—obesity	4.36e-07	3.46e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAV1—obesity	4.35e-07	3.45e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOA1—obesity	4.34e-07	3.44e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2E1—obesity	4.34e-07	3.44e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—obesity	4.34e-07	3.44e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—obesity	4.33e-07	3.44e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—obesity	4.33e-07	3.44e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—obesity	4.33e-07	3.43e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARA—obesity	4.32e-07	3.43e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—obesity	4.32e-07	3.43e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—obesity	4.32e-07	3.43e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—INS—obesity	4.31e-07	3.42e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—obesity	4.3e-07	3.41e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—obesity	4.3e-07	3.41e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NQO1—obesity	4.29e-07	3.4e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—obesity	4.25e-07	3.37e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—obesity	4.24e-07	3.37e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—obesity	4.24e-07	3.36e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AGT—obesity	4.22e-07	3.35e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—obesity	4.22e-07	3.35e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—obesity	4.22e-07	3.34e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—obesity	4.2e-07	3.33e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AGT—obesity	4.19e-07	3.32e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—obesity	4.14e-07	3.28e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CB—obesity	4.12e-07	3.27e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCG—obesity	4.11e-07	3.26e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A4—obesity	4.11e-07	3.26e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—obesity	4.1e-07	3.26e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAV1—obesity	4.1e-07	3.25e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK8—obesity	4.1e-07	3.25e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOA1—obesity	4.09e-07	3.25e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—obesity	4.09e-07	3.24e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—obesity	4.08e-07	3.24e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAV1—obesity	4.07e-07	3.23e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYCS—obesity	4.06e-07	3.22e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOA1—obesity	4.06e-07	3.22e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—obesity	4.05e-07	3.21e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—obesity	4.04e-07	3.2e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—obesity	4.03e-07	3.2e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—obesity	4.02e-07	3.19e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CD—obesity	4e-07	3.17e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GOT1—obesity	3.99e-07	3.16e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GGT1—obesity	3.99e-07	3.16e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CG—obesity	3.96e-07	3.15e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—obesity	3.95e-07	3.13e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NCOA1—obesity	3.93e-07	3.11e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—obesity	3.91e-07	3.1e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—obesity	3.88e-07	3.08e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—obesity	3.88e-07	3.08e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—STK11—obesity	3.87e-07	3.07e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP19A1—obesity	3.87e-07	3.07e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—obesity	3.83e-07	3.04e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—obesity	3.83e-07	3.03e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3R1—obesity	3.78e-07	3e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—obesity	3.78e-07	3e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—obesity	3.77e-07	2.99e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—INS—obesity	3.75e-07	2.98e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—obesity	3.75e-07	2.97e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—obesity	3.74e-07	2.97e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CG—obesity	3.74e-07	2.96e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—obesity	3.74e-07	2.96e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CG—obesity	3.7e-07	2.94e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—obesity	3.68e-07	2.92e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—obesity	3.62e-07	2.87e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—obesity	3.61e-07	2.86e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—obesity	3.61e-07	2.86e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—COMT—obesity	3.6e-07	2.85e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—obesity	3.57e-07	2.84e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—obesity	3.56e-07	2.82e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNB3—obesity	3.55e-07	2.81e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARGC1A—obesity	3.55e-07	2.81e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—INS—obesity	3.54e-07	2.81e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMOX1—obesity	3.53e-07	2.8e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—obesity	3.53e-07	2.8e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—obesity	3.53e-07	2.8e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—INS—obesity	3.51e-07	2.78e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CB—obesity	3.49e-07	2.77e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CD—obesity	3.49e-07	2.76e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—obesity	3.48e-07	2.76e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—obesity	3.47e-07	2.76e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—obesity	3.46e-07	2.74e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNAS—obesity	3.45e-07	2.74e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—obesity	3.45e-07	2.74e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—obesity	3.44e-07	2.73e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—obesity	3.43e-07	2.72e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—obesity	3.42e-07	2.71e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOB—obesity	3.38e-07	2.68e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—obesity	3.34e-07	2.65e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—obesity	3.3e-07	2.62e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3R1—obesity	3.29e-07	2.61e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—obesity	3.29e-07	2.61e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CD—obesity	3.28e-07	2.61e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—obesity	3.26e-07	2.59e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CD—obesity	3.26e-07	2.58e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—obesity	3.24e-07	2.57e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LPL—obesity	3.23e-07	2.56e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—obesity	3.21e-07	2.55e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—obesity	3.19e-07	2.53e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPX1—obesity	3.15e-07	2.5e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3R1—obesity	3.1e-07	2.46e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—obesity	3.1e-07	2.46e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3R1—obesity	3.07e-07	2.44e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—obesity	3.07e-07	2.44e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CD36—obesity	3.07e-07	2.43e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CB—obesity	3.04e-07	2.41e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—obesity	3.03e-07	2.4e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—obesity	3.01e-07	2.39e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—obesity	3.01e-07	2.39e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—obesity	2.96e-07	2.35e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—obesity	2.95e-07	2.34e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—obesity	2.91e-07	2.31e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CB—obesity	2.86e-07	2.27e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARA—obesity	2.85e-07	2.26e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CB—obesity	2.84e-07	2.25e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—obesity	2.84e-07	2.25e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—obesity	2.81e-07	2.23e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—obesity	2.8e-07	2.22e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—obesity	2.79e-07	2.22e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AGT—obesity	2.76e-07	2.19e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—obesity	2.71e-07	2.15e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAV1—obesity	2.68e-07	2.13e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOA1—obesity	2.68e-07	2.12e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—obesity	2.62e-07	2.08e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—obesity	2.51e-07	1.99e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CG—obesity	2.44e-07	1.94e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—obesity	2.42e-07	1.92e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—obesity	2.36e-07	1.87e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—obesity	2.33e-07	1.84e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—INS—obesity	2.31e-07	1.83e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CD—obesity	2.15e-07	1.7e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—obesity	2.13e-07	1.69e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—obesity	2.12e-07	1.68e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—obesity	2.05e-07	1.63e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3R1—obesity	2.03e-07	1.61e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—obesity	2.03e-07	1.61e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CB—obesity	1.87e-07	1.48e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—obesity	1.85e-07	1.47e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—obesity	1.85e-07	1.47e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—obesity	1.75e-07	1.38e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—obesity	1.74e-07	1.38e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—obesity	1.73e-07	1.37e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—obesity	1.51e-07	1.2e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—obesity	1.43e-07	1.13e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—obesity	1.41e-07	1.12e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—obesity	1.14e-07	9.05e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—obesity	9.32e-08	7.39e-07	CbGpPWpGaD
